Cantor Fitzgerald Reaffirms “Overweight” Rating for Voyager Therapeutics (NASDAQ:VYGR)

Voyager Therapeutics (NASDAQ:VYGR)‘s stock had its “overweight” rating reaffirmed by equities researchers at Cantor Fitzgerald in a research report issued on Wednesday,Benzinga reports.

Several other research analysts also recently issued reports on the company. Wedbush reaffirmed an “outperform” rating and set a $9.00 price target (down previously from $11.00) on shares of Voyager Therapeutics in a research note on Tuesday, February 11th. Canaccord Genuity Group reaffirmed a “buy” rating and set a $14.00 price target on shares of Voyager Therapeutics in a research note on Thursday, November 14th. Citigroup initiated coverage on Voyager Therapeutics in a research note on Monday, December 2nd. They set a “buy” rating and a $12.00 price target for the company. StockNews.com downgraded Voyager Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, December 13th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $30.00 price target on shares of Voyager Therapeutics in a research note on Monday, March 3rd. One investment analyst has rated the stock with a hold rating, nine have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus target price of $14.86.

Voyager Therapeutics Stock Performance

Voyager Therapeutics stock opened at $4.07 on Wednesday. Voyager Therapeutics has a one year low of $3.56 and a one year high of $10.66. The business has a fifty day moving average of $4.91 and a two-hundred day moving average of $5.86. The company has a market cap of $222.33 million, a P/E ratio of 5.73 and a beta of 0.99.

Voyager Therapeutics (NASDAQ:VYGR) last released its earnings results on Tuesday, March 11th. The company reported ($0.59) EPS for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.24). Voyager Therapeutics had a net margin of 15.80% and a return on equity of 8.33%. The business had revenue of $4.39 million during the quarter, compared to analyst estimates of $16.58 million. During the same period last year, the business posted $1.25 EPS. Sell-side analysts predict that Voyager Therapeutics will post -0.91 EPS for the current year.

Insider Buying and Selling

In other Voyager Therapeutics news, COO Robin Swartz sold 6,500 shares of Voyager Therapeutics stock in a transaction dated Monday, December 23rd. The stock was sold at an average price of $5.65, for a total value of $36,725.00. Following the completion of the sale, the chief operating officer now owns 112,328 shares in the company, valued at $634,653.20. The trade was a 5.47 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In the last quarter, insiders sold 10,778 shares of company stock worth $58,548. 4.53% of the stock is owned by corporate insiders.

Institutional Trading of Voyager Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. grew its holdings in Voyager Therapeutics by 0.9% in the 4th quarter. Vanguard Group Inc. now owns 3,215,441 shares of the company’s stock valued at $18,232,000 after buying an additional 29,014 shares during the period. Farallon Capital Management LLC grew its holdings in shares of Voyager Therapeutics by 12.2% during the 4th quarter. Farallon Capital Management LLC now owns 2,570,700 shares of the company’s stock worth $14,576,000 after purchasing an additional 278,700 shares during the period. Dimensional Fund Advisors LP grew its holdings in shares of Voyager Therapeutics by 24.9% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,380,615 shares of the company’s stock worth $7,828,000 after purchasing an additional 275,571 shares during the period. Vestal Point Capital LP grew its holdings in shares of Voyager Therapeutics by 151.0% during the 4th quarter. Vestal Point Capital LP now owns 1,230,000 shares of the company’s stock worth $6,974,000 after purchasing an additional 740,000 shares during the period. Finally, Geode Capital Management LLC grew its holdings in shares of Voyager Therapeutics by 0.4% during the 4th quarter. Geode Capital Management LLC now owns 1,084,238 shares of the company’s stock worth $6,149,000 after purchasing an additional 4,729 shares during the period. Hedge funds and other institutional investors own 48.03% of the company’s stock.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.